头孢曲松钠联合匹多莫德治疗梅毒血清固定患者的疗效及对NK、CD4^+、CD3^+细胞水平的影响

Influence and effect of ceftriaxone combiend with pidotimod on NK,CD4^+and CD3^+cell levels for syphilis serofast patients

目的探讨匹多莫德和头孢曲松钠联合治疗梅毒血清固定患者的临床效果及对NK、CD4+、CD3+细胞水平的影响。方法选择2018年4月至2019年2月在海口市人民医院接受诊治的梅毒血清固定患者80例,根据随机对照法分组,分为观察组和对照组,每组40例。观察组予以匹多莫德和头孢曲松钠联合治疗,对照组予以头孢曲松钠治疗,两组均治疗2个月。比较两组治疗前、治疗2个月后NK、CD4+、CD3+细胞水平变化;比较两组治疗后3个月、治疗后半年、治疗后9个月、治疗后1年快速血浆反应素环状卡片试验(RPR)滴度转阴率;比较两组治疗后的临床效果。结果两组治疗2个月后NK、CD4+、CD3+细胞水平均有升高,且观察组治疗2个月后的NK、CD4+、CD3+细胞水平高于对照组,差异有统计学意义(P<0.05);观察组治疗后有效32例(80.0%),对照组治疗后有效21例(52.5%),两组比较差异有统计学意义(P<0.05);观察组治疗后3个月、治疗后半年、治疗后9个月、治疗后1年RPR滴度转阴率明显高于对照组,差异有统计学意义(P<0.05)。结论梅毒血清固定患者予以匹多莫德和头孢曲松钠联合治疗可提高RPR滴度转阴率,提高机体免疫细胞水平,临床效果确切,值得临床推广。

Objective To study the influence and effect of ceftriaxone combiend with pidotimod on NK,CD4+and CD3+cell levels for syphilis serofast patients.Methods Totally 80 syphilis serofast patients treated from April 2018 to February 2019 in the hospital were selected and randomly assigned to control group and observation group,40 cases in each group.The observation group took the combined therapy of pidotimod and ceftriaxone,and the control group just took ceftriaxone treatment.Both groups were treated for 2 months,NK,CD4+and CD3+cell levels before treatment and 2 months after treatment were compared,the negative conversion rates of ring card test of rapid plasma regain(RPR)after 3,6,9 months and 1 year of treatment were compared,and therapeutic outcomes were assessed.Results After 2 months of treatment,the levels of NK,CD4+and CD3+cells in two groups were increased,but the levels of NK,CD4+and CD3+cells in the observation group were higher than those in the control group,and the differences were statistically significant between two groups(P<0.05).The treament was effective in 32 cases in the observation group(80.0%)and 21 cases in the control group(52.5%),and the differences were statistically significant(P<0.05).The negative conversion rates of RPR after 3,6,9 months and 1 year of treatment in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The combined therapy of pidotimod and ceftriaxone can increase the negative conversion rates of RPR and patients′immune cell levels.It has accurate clinical effect and is worthy of clinical promotion.